Literature DB >> 18793990

Calciphylaxis.

Esteban Daudén1, María-Jesús Oñate.   

Abstract

Calciphylaxis is defined by the presence of calcium deposits within the wall of small and medium-sized vessels. It is classically considered a life-threatening disease in patients with end-stage renal disease under dialysis. Clinically, it is characterized by the presence of painful plaques surrounded by a reticulate purpura that progresses to nonhealing ulcers, predominately in the lower limbs. It is associated with elevated parathyroid hormone levels and a dysregulation of the calcium/phosphate metabolism. In the absence of renal disease, normal parathyroid hormone levels, and calcium/phosphorus product, a good prognosis and the observation of similar calcium deposits associated with different conditions or even an epiphenomenon in diseases with well-known diagnosis leads one to consider the term calciphylaxis controversial.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793990     DOI: 10.1016/j.det.2008.05.006

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  18 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

Review 2.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

3.  Non-uraemic calciphylaxis successfully treated with pamidronate infusion.

Authors:  David H Truong; Marcus M Riedhammer; Kathya Zinszer
Journal:  Int Wound J       Date:  2018-11-04       Impact factor: 3.315

Review 4.  Calciphylaxis: diagnosis and clinical features.

Authors:  Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2013-02-21       Impact factor: 2.801

5.  Penile calciphylaxis in a patient on combined peritoneal dialysis and hemodialysis.

Authors:  Takahiro Kasai; Naoki Washida; Hirokazu Muraoka; Kentarou Fujii; Kiyotaka Uchiyama; Keisuke Shinozuka; Kohkichi Morimoto; Hirobumi Tokuyama; Shu Wakino; Hiroshi Itoh
Journal:  CEN Case Rep       Date:  2018-03-28

Review 6.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

7.  Use of the optimized sodium thiosulfate regimen for the treatment of calciphylaxis in Chinese patients.

Authors:  Xin Yang; Yuqiu Liu; Xiaotong Xie; Wen Shi; Jiyi Si; Xiaomin Li; Xiaoliang Zhang; Bicheng Liu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 8.  Cutaneous manifestations of ESRD.

Authors:  Timur A Galperin; Antonia J Cronin; Kieron S Leslie
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

9.  Calcific uremic arteriolopathy in peritoneal dialysis populations.

Authors:  Nicholas New; Janaki Mohandas; George T John; Sharad Ratanjee; Helen Healy; Leo Francis; Dwarakanathan Ranganathan
Journal:  Int J Nephrol       Date:  2011-06-27

10.  Pilot Study of the Effect of Lanthanum Carbonate (Fosrenol®) In Patients with Calciphylaxis: A Wisconsin Network for Health Research (WiNHR) Study.

Authors:  Micah R Chan; Fadi Ghandour; Narayana S Murali; Mj Washburn; Brad C Astor
Journal:  J Nephrol Ther       Date:  2014-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.